B
MRNS

Bailard’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Bailard’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,250
Closed -$137K – 607
2019
Q2 		$137K Hold
8,250
– – 0.01% 524
2019
Q1 		$138K Buy
+8,250
New +$119K 0.01% 519

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bailard's MRNS Position: Q3 2019 in Review

Bailard sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2019, closing a stake of 8,250 shares — an estimated $137K sold.

Bailard first reported a position in MRNS in Q1 2019 and held it in 2 quarters. The position peaked at $138K in Q1 2019. 64 funds tracked by Wall St. Rank hold MRNS as of Q3 2019.

  • Bailard reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2019 after selling out during the quarter.
  • Bailard sold 8,250 Marinus Pharmaceuticals, Inc shares in Q3 2019, an estimated $137K.
  • Bailard first reported a position in Marinus Pharmaceuticals, Inc in Q1 2019 and held it in 2 quarters.
  • Bailard's Marinus Pharmaceuticals, Inc position peaked at $138K in Q1 2019.
  • 64 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2019.

Based on Bailard's 13F filing for Q3 2019, filed 18 Oct 2019.